Extensive crosstalk between GR signaling and other steroid receptors, including ER, PR, androgen receptor (AR), and mineralocorticoid receptor (MR), have been described in breast cancer in detail [39, 64, 105-107]. Here, NR3C2 is linked to breast carcinoma.